Mayo Clinic Laboratory and pathology research roundup: February 22
Share this:
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
Deep residual inception encoder-decoder network for amyloid PET harmonization.
Multiple positron emission tomography (PET) tracers are available for amyloid imaging, posing a significant challenge to consensus interpretation and quantitative analysis. We accordingly developed and validated a deep learning model as a harmonization strategy.
Published to PubMed This Week
- Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
Nature Communications - Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis.
Leukemia - Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.
Clinical Cancer Research - Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).
Blood Cancer Journal - Anti-neuronal nuclear antibody 3 autoimmunity targets dachshund homolog 1.
Annals of Neurology - Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome.
Journal of Neurology, Neurosurgery and Psychiatry - Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
American Journal Hemotology - Prognostic significance of acquired 1q22 gain in multiple myeloma.
American Journal Hemotology - SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.
Haematologica - Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: The Mayo Clinic experience.
Haematologica
